The phase 2/3 GATHER1 trial showed patients with geographic atrophy due to age-related macular degeneration who received avacincaptad pegol experienced a 28% reduction in rate of geographic atrophy growth over 18 months.
Donald J. D’Amico, MD, presented the results at Retina Subspecialty Day at the virtual American Academy of Ophthalmology meeting.
“The GATHER1 study achieved the primary efficacy endpoint for reduction in the growth rate of geographic atrophy for both the 2 mg and 4 mg doses of avacincaptad vs. sham,” he said.
The trial was implemented in two parts. Patients
Uncategorized